Biogen Wins US Approval for Drug to Treat Rare Form of ALS - BNN Bloomberg
What clinical trials of the future might look like | Biogen
Biogen gives up releasing Alzheimer's drug Aduhelm in Korea < Pharma < Article - KBR
Biogen boosts Aduhelm confirmatory trial amid fight for wider Medicare coverage | Fierce Pharma
CSRWire - Redefining What A Scientist Looks Like: Biogen Leaders Discuss the Importance of Women in STEM
Biogen targets 'lost to follow-up' patients in MS campaign - PMLiVE
Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more
Biogen - Home | Facebook
Biogen grapples with 'reckoning' over controversial Alzheimer's drug, reporters find | WBUR News
More Layoffs Hit Biogen as Drugmaker Cuts Multiple Sclerosis Team – NBC Boston
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
For women, business as unusual at Biogen - The Boston Globe
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Biogen's Qalsody Is a First for ALS Treatments - Bloomberg
Biogen's ALS Drug Tofersen Gets Partial Backing From FDA Panel - Bloomberg
Biogen Announces Positive Phase 1 Results, Plan to License and Develop Ionis Pharmaceuticals' Investigational Therapy BIIB067 for Familial ALS - Muscular Dystrophy Association
UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization | Fierce Biotech
Biogen, at a Crossroads, Surges on Promising Alzheimer's Drug Assessment - WSJ
Dr BABOR Biogen Cellular - The Goddess Beauty and ...
Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer's Drug. | Barron's
Judge axes Biogen class action, rips shareholder lawyers for 'constant misrepresentation' | Reuters
Biogen (BIIB) Loses Bid to Revive Patent on Tecfidera MS Drug - Bloomberg
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research | The Scientist Magazine®
Biogen's new Alzheimer's drug slows cognitive decline: study - Boston Business Journal
